Elena Élez, MD, PhD, discusses quality of life outcomes with combination checkpoint blockade in patients with microsatellite instability-high mCRC.
Elena Élez, MD, PhD
Advertisement
Elena Élez, mD, PhD, is Medical Oncology consultant at Vall d'Hebron University Hospital and senior investigator at Vall d'Hebron Institute of Oncology.
Articles by Elena Élez, MD, PhD
Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.
Elena Élez, MD, PhD, discusses the evolving role of immunotherapy for patients with microsatellite instability–high metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr Élez on Health-Related QOL With Nivolumab Plus Ipilimumab in mCRCPublished: September 2nd 2025 | Updated:
Dr Elez on the Rationale for Evaluating QOL Outcomes With ICI Doublets in mCRCPublished: September 30th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5